ajd-diabete.fr/le-diabete/les-autres-types-de-diabete/le-diabete-detype-mody, 2014. ,
Histologie l'essentiel. Maloine. Sciences fondamentales, 2002. ,
Atlas du diabète de la FID, 2013. ,
« The incidence of comorbidities related to obesity and overweight : a systematic review and meta-analysis », BMC Public Health, vol.9, p.88, 2009. ,
« New treatments of type 2 diabetes : which therapeutic strategies for the future ?, Sang Thrombose Vaisseaux, vol.21, issue.8, pp.397-407, 2009. ,
Guide pratique du diabète. 5ème édition, 2013. ,
« Glucagon-like Peptide Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Diabetes: A Review of, Clinical Trials ». Current Opinion in Clinical Nutrition and Metabolic Care, vol.11, issue.4, pp.491-99, 2008. ,
« Investigational Anti-Hyperglycemic Agents: The Future of Type 2 Diabetes Therapy ?, Endocrine, vol.44, issue.1, pp.47-58, 2013. ,
« Glucagon-like Peptide 1(GLP-1) in Biology and Pathology, Diabetes/Metabolism Research and Reviews, vol.21, issue.2, pp.91-117, 2005. ,
« Prise en charge du diabète de type 2 : l'éducation thérapeutique, Prise en charge du diabète de type 2, pp.42-880, 2013. ,
L'insulinothérapie dans le diabète de type 2. De la théorie à la pratique, 2014. ,
« Incretin-based therapy: how do incretin mimetics and DPP- 4 inhibitors fit into treatment algorithms for type 2 diabetic patients?, Best Practice & Research Clinical Endocrinology & Metabolism, Incretins, vol.23, issue.4, pp.513-536, 2009. ,
« Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4), Best Practice & Research Clinical Endocrinology & Metabolism, Incretins, vol.23, issue.4, pp.479-86, 2009. ,
« Exenatide added to insulin therapy : a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting », Clin Ther, vol.31, pp.1511-1534, 2009. ,